Atlas Crest Investment Corp (ACIC) Peer Comparison
$9.54
$1.12
(13.30%)
As on 04-Sep-2026 16:00EDT
Market cap
$451 Mln
Revenue (TTM)
$330 Mln
P/E Ratio
4.7
P/B Ratio
1.3
Div. Yield
0 %
Edit
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
451 | 5,749 | 3,324 | 746 | 373 |
Revenue ($ Mln) |
330 | 440 | 2,883 | -- | 58 |
Net Profit ($ Mln) |
100.20 | -1,435.01 | -118.30 | -134.20 | -50.70 |
Net Margin (%) |
30.33 | -325.91 | -4.10 | -- | -88.09 |
RoE (%) |
30.44 | -- | -- | -40.17 | -54.90 |
Price to Earnings |
4.72 | -- | -- | -- | -- |
Price-To-Book |
1.32 | -- | 1.35 | -- | 2.54 |
Income Statement ($ Mln)
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
335.44 | 319.02 | 2,631.80 | -- | 45.97 |
|
Cost of Revenue
|
46.04 | 281.12 | 1,584.40 | -- | 53.38 |
|
Gross Profit
|
289.40 | 37.90 | 1,047.40 | -- | -7.40 |
|
Operating Expenses
|
146.67 | 262.45 | 899.40 | 0.17 | 47.52 |
|
Operating Profit (EBIT)
|
142.73 | -224.55 | 148.00 | -0.17 | -54.92 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
142.73 | -288.03 | -159.30 | 0.38 | -71.25 |
|
Provision for Tax
|
35.94 | 0.58 | 16.20 | -- | 0.12 |
|
Profit after Tax (Net Income)
|
106.84 | -288.62 | -198.30 | 0.38 | -71.36 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
317.57 | -962.74 | -1,276.40 | 399.79 | 38.16 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
160.23 | 2,528.98 | 3,507.00 | 15.99 | 33.39 |
|
Current Liabilities
|
594.94 | 781.40 | 2,868.70 | 0.13 | 33.80 |
|
Total Liabilities
|
1,072.73 | 2,347.64 | 5,244.20 | 415.91 | 105.35 |
Assets ($ Mln)
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
349.32 | 1,452.11 | 3,924.70 | 414.85 | 26.39 |
|
Current Assets
|
723.41 | 895.54 | 1,319.50 | 1.06 | 78.96 |
|
Total Assets
|
1,072.73 | 2,347.64 | 5,244.20 | 415.91 | 105.35 |
|
Total Debt*
|
152.49 | 1,060.33 | 3,975.30 | -- | 40.23 |
|
Net Current Assets
|
-- | 114.14 | -1,558.20 | 0.93 | 46.32 |
Cashflow ($ Mln)
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
71.03 | 278.25 | 24.80 | -0.63 | -27.33 |
|
Cash Flow from Investing Activities
|
0.62 | -740.75 | -12.20 | -414.00 | -2.72 |
|
Cash from Financing Activities
|
-1.08 | -63.10 | 114.30 | 415.37 | 67.83 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
24.90 | -120.97 | -7.47 | -- | -106.54 |
|
ROE (%)
|
38.62 | 32.38 | 17.08 | -- | -183.40 |
|
ROA (%)
|
9.34 | -14.63 | -3.83 | -- | -73.37 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
31.85 | -90.47 | -7.53 | -- | -155.23 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.13 | -0.38 | -0.18 | -- | 0.12 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
41.10 | 78.05 | -54.32 | -- | -2.32 |
|
EPS Growth (%)
|
0.40 | 0.80 | -0.54 | -- | -14.54 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
5.90 | -19.80 | -13.35 | -- | -4.10 |
|
Price / Book Value
|
1.99 | -5.94 | -2.07 | -- | 7.67 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
2.71 | -31.10 | 5.65 | -- | -4.37 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.48 | -1.10 | -3.11 | -- | 1.05 |
|
Short term debt to equity ratio
|
0.00 | -0.03 | -1.08 | -- | 0.22 |
|
Current Ratio
|
1.22 | 1.15 | 0.46 | 8.13 | 2.34 |
|
Quick Ratio
|
-- | -- | -- | -- | 1.53 |
|
Interest Coverage
|
14.20 | -87.90 | 0.39 | -- | 0.00 |
Operating Efficiency Ratios
| Atlas Crest Investment Corp (ACIC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
61.95 | 105.69 | 29.34 | -- | 18.06 |
|
Asset Turnover
|
0.29 | 0.16 | 0.51 | -- | 0.47 |
|
Receivable days
|
281.90 | 193.60 | 125.70 | -- | 49.75 |
|
Inventory Days
|
-1,881.69 | -5.77 | -5.88 | -- | 263.57 |
|
Payable days
|
1,383.94 | 94.44 | 58.42 | -- | 98.67 |
|
Cash Conversion Cycle
|
-1,771.50 | -84.42 | 68.68 | -- | 214.66 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
